Reported about 1 year ago
Despite Pfizer's stock decline, the pharmaceutical company raised its dividend for the 15th consecutive year, offering a 6.1% yield. Sales of Pfizer's COVID-19 vaccine and antiviral treatment were strong, but the stock suffered due to unexpected sales drops. However, Pfizer made smart investments in acquiring new drugs and expects adjusted earnings to support its dividend commitment. While caution is needed due to potential sales deceleration of some key products, investing in Pfizer for the long term seems promising for most investors.
Source: YAHOO